Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dennis Bourdette

Showing results (1-10 of 140) with videos related to

Pageof 14
Sort By:
Neurology|June 13, 2014
Alemtuzumab and multiple sclerosis: is it safe?Dennis Bourdette
Neurology|October 21, 2016
Rituximab for treating multiple sclerosis: Off-label but on targetDennis Bourdette
The Lancet. Neurology|November 26, 2020
Are drugs for multiple sclerosis fatigue just placebos?Dennis Bourdette
Neurology|August 28, 2024
Investigating When Patients With Multiple Sclerosis Should Switch From a Low- or Moderate-Efficacy Therapy to a High-Efficacy TreatmentDennis Bourdette
Neurology|September 11, 2002
Depression is a treatable cause of suffering among multiple sclerosis patients and can result in suicideDennis Bourdette
Current Neurology and Neuroscience Reports|August 21, 2008
B-cell depletion with rituximab in relapsing-remitting multiple sclerosisDennis Bourdette, Vijayshree Yadav
Current Neurology and Neuroscience Reports|August 12, 2009
Alemtuzumab versus interferon beta-1a in early multiple sclerosisDennis Bourdette, Vijayshree Yadav
Current Neurology and Neuroscience Reports|June 25, 2010
Oral disease-modifying therapies for multiple sclerosis: are we there yet?Vijayshree Yadav, Dennis Bourdette
Neurology. Clinical Practice|November 7, 2013
Postmarketing adverse drug reactions: A duty to report?Eran Klein, Dennis Bourdette
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 14, 2022
Polypharmacy in multiple sclerosis: More is not necessarily betterDennis Bourdette, Megan Herink
Pageof 14

Showing results (1-10 of 140) with videos related to

Sort By:
Pageof 14
Neurology|June 13, 2014
Alemtuzumab and multiple sclerosis: is it safe?Dennis Bourdette
Neurology|October 21, 2016
Rituximab for treating multiple sclerosis: Off-label but on targetDennis Bourdette
The Lancet. Neurology|November 26, 2020
Are drugs for multiple sclerosis fatigue just placebos?Dennis Bourdette
Neurology|August 28, 2024
Investigating When Patients With Multiple Sclerosis Should Switch From a Low- or Moderate-Efficacy Therapy to a High-Efficacy TreatmentDennis Bourdette
Neurology|September 11, 2002
Depression is a treatable cause of suffering among multiple sclerosis patients and can result in suicideDennis Bourdette
Current Neurology and Neuroscience Reports|August 21, 2008
B-cell depletion with rituximab in relapsing-remitting multiple sclerosisDennis Bourdette, Vijayshree Yadav
Current Neurology and Neuroscience Reports|August 12, 2009
Alemtuzumab versus interferon beta-1a in early multiple sclerosisDennis Bourdette, Vijayshree Yadav
Current Neurology and Neuroscience Reports|June 25, 2010
Oral disease-modifying therapies for multiple sclerosis: are we there yet?Vijayshree Yadav, Dennis Bourdette
Neurology. Clinical Practice|November 7, 2013
Postmarketing adverse drug reactions: A duty to report?Eran Klein, Dennis Bourdette
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 14, 2022
Polypharmacy in multiple sclerosis: More is not necessarily betterDennis Bourdette, Megan Herink
Pageof 14